Indena Boswellia formulation shown to alleviate IBS symptoms

c0a9d50b-0fb2-4101-93dc-21f851aa1f47articleimage.jpg

17 Jul 2017 --- A new study has shown that Casperome, the Indena Phytosome formulation of Boswellia serrate that delivers the full natural bouquet of triterpenoids, offers rapid relief to sufferers of irritable bowel syndrome (IBS). Affecting 10 to 20 percent of the adult population and often unrecognized or untreated, Irritable bowel syndrome (IBS) is a chronic, relapsing gastrointestinal disorder. 

 

The supplement registry study, published in the European Review for Medical and Pharmacological Sciences, enrolled 71 otherwise healthy subjects with idiopathic IBS that each decided to follow a different management strategy. Group one took Hyoscine butylbromide, administered when needed. Group two took 10mg of papaverine hydrochloride and 10mg of belladonna extract, administered when needed. Group three used a supplementation with Casperome, one tablet of 250mg per day, for four weeks. All groups were comparable in term of age and gender distribution and they presented similar clinical characteristics at inclusion. Abdominal pain, altered bowel movements, meteorism and cramps were evaluated by subjects before the inclusion and during the last week before the end of the observational period of four weeks.

All IBS symptoms investigated improved during the period with the three management strategies, but only in the Casperome-supplemented group did the number of subjects with any IBS symptoms significantly decrease, from 58 percent to 12.5 percent. In the Casperome-supplemented group, the number of subjects who needed medical attention significantly decreased to 4.1 percent. In addition, the prevalence of side effects was significantly higher in the two groups treated with the Standard Management Strategies (28 percent for group one and 26 percent for group two) compared to Casperome supplemented subjects (8.2 percent). 

This study demonstrates that Indena’s Casperome supplementation may represent a promising alternative approach to managing symptoms associated with IBS in otherwise healthy subjects.

RELATED ARTICLES
Homepicture

Seventure Partners’ microbiome portfolio nears critical milestones 

18 Dec 2017 Seventure Partners, one of Europe’s ...

Homepicture

Nutrition 21 launches US media campaign to support Velositol ingredient

11 Dec 2017 Nutrition 21, LLC has partnered with NYC-based ...

Homepicture

Inflammatory bowel disease rates on the rise outside West, says new study

08 Dec 2017 Countries in Africa, Asia, the Middle East and ...

Homepicture

Consuming sugary drinks during pregnancy may increase asthma risk in mid-childhood

08 Dec 2017 Children between the ages of 7 and 9 may be at ...